Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Premier, Inc. Reports Fiscal Year 2023 First Quarter Results: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Reports Fiscal Year 2023 First Quarter Results


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today reported financial results for the fiscal year 2023 first quarter ended September 30, 2022.



"Our

PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOKhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK


Pfizer Inc. (NYSE: PFE) reported solid financial results for third-quarter 2022 and updated certain components of 2022 financial guidance(4). Pfizer raised the lower end of its 2022 revenue

Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidatehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate


Pfizer Inc. (NYSE: PFE) today announced positive top-line data from the Phase 3 clinical trial (NCT04424316) MATISSE (MATernal Immunization Study for Safety and Efficacy) investigating its bivalent

Chemed Reports Third-Quarter 2022 Results - Increases 2022 Earnings Guidance:
Chemed Reports Third-Quarter 2022 Results - Increases 2022 Earnings Guidance


Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest

Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will

Chemed Corporation to Present at the 2022 Credit Suisse Healthcare Conference:
Chemed Corporation to Present at the 2022 Credit Suisse Healthcare Conference


Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the 31st Annual Credit Suisse Healthcare Conference on Wednesday, November 9, 2022, at approximately 2:00 p.m

Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat


Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations

Dexcom Reports Third Quarter 2022 Financial Results: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Reports Third Quarter 2022 Financial Results


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2022.



Third Quarter 2022 Financial Highlights:




  • Revenue grew 18% versus the same

Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast: https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its third quarter 2022 financial results after the market closes on

Labcorp Announces 2022 Third Quarter Results: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24603/300px-LabCorp.svg.png
Labcorp Announces 2022 Third Quarter Results


Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the third quarter ended Sept. 30, 2022, and updated full-year guidance.



"Labcorp made important strategic

Novocure Reports Third Quarter 2022 Financial Results: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Reports Third Quarter 2022 Financial Results


Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive

Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented updated findings from the Phase II SUMMIT basket trial of neratinib for EGFR exon 18-mutant non-small cell lung

Simulations Plus Reports Fourth Quarter and Full Fiscal Year 2022 Financial Results: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Reports Fourth Quarter and Full Fiscal Year 2022 Financial Results


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its fourth

Humana, Monogram Health Announce New Agreement that Enhances In-home Kidney Care in Four States: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana, Monogram Health Announce New Agreement that Enhances In-home Kidney Care in Four States


Kidney care provider Monogram Health and leading health and well-being company Humana Inc. (NYSE: HUM) have announced a new value-based care agreement for most Humana Medicare Advantage HMO and PPO

Vistagen to Host Concordia Live Webinar on Mental Health with Leaders from McKinsey Health Institute, WEVO, and In KidZ: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen to Host Concordia Live Webinar on Mental Health with Leaders from McKinsey Health Institute, WEVO, and In KidZ


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous

Humana expands Medicare Advantage health plan offerings into Rhode Island, Wyoming and 140 new counties nationwide in 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana expands Medicare Advantage health plan offerings into Rhode Island, Wyoming and 140 new counties nationwide in 2023


Leading health and well-being company Humana Inc. (NYSE: HUM) is offering Medicare Advantage plans for the first time in two new states and 140 new U.S. counties, expanding cost-effective health

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting


Novocure (NASDAQ: NVCR) today announced 11 poster presentations on Tumor Treating Fields (TTFields) will be featured at the American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting from

Premier, Inc. Declares Quarterly Cash Dividend: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Declares Quarterly Cash Dividend


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common

Simulations Plus Announces Cash Dividend: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Announces Cash Dividend


Simulations Plus, Inc. (Nasdaq: SLP) announced today that the Company’s Board of Directors has declared a cash dividend of $0.06 per share of the Company’s common stock, payable on November 7

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, Nov. 3, 2022, following the release of its third

Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology


Novocure (NASDAQ: NVCR) today announced a review article of anti-cancer mechanisms of action of Tumor Treating Fields (TTFields) has been published in the Journal of Molecular Cell Biology (JMCB).

Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy


Novocure (NASDAQ: NVCR) today announced the launch of a campaign intended to drive awareness and understanding of Tumor Treating Fields (TTFields) therapy as a distinct anticancer modality and an

Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022


Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression

Charles River Launches HemaCare Donor App to Engage Diverse Donors and Source Cell Solutions for Critical Cell and Gene Therapy Research: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Launches HemaCare Donor App to Engage Diverse Donors and Source Cell Solutions for Critical Cell and Gene Therapy Research


Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of a new digital donor experience to enhance access to its donor centers in four distinct US geographic markets

STAAR Surgical to Report Third Quarter Results on November 2, 2022: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical to Report Third Quarter Results on November 2, 2022


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release